July 18, 2024 - $Intuitive Surgical (ISRG.US)$ shares rose 6.81% to $444.49 in post-market trading on Thursday. The company announced financial results for the quarter ended June 30, 2024.
Q2 Highlights
Worldwide da Vinci procedures grew approximately 17% compared with the second quarter of 2023.
The Company placed 341 da Vinci surgical systems, compared with 331 in the second quarter of 2023. The second quarter 2024 da Vinci surgical system placements included 70 da Vinci 5 systems.
The Company grew its da Vinci surgical system installed base to 9,203 systems as of June 30, 2024, an increase of 14% compared with 8,042 as of the end of the second quarter of 2023.
Second quarter 2024 revenue of $2.01 billion increased 14% compared with $1.76 billion in the second quarter of 2023.
Second quarter 2024 GAAP net income attributable to Intuitive was $527 million, or $1.46 per diluted share, compared with $421 million, or $1.18 per diluted share, in the second quarter of 2023.
Second quarter 2024 non-GAAP net income attributable to Intuitive was $641 million, or $1.78 per diluted share, compared with $507 million, or $1.42 per diluted share, in the second quarter of 2023.
About Company
$Intuitive Surgical (ISRG.US)$, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.
2024 年 7 月 18 日- $直觉外科公司 (ISRG.US)$ 周四盘后交易中,股价上涨6.81%,至444.49美元。该公司公布了截至2024年6月30日的季度财务业绩。
第二季度亮点
与2023年第二季度相比,全球达芬奇手术增长了约17%。
该公司放置了341套达芬奇手术系统,而2023年第二季度为331套。2024年第二季度达芬奇手术系统的部署包括70套达芬奇5系统。
截至2024年6月30日,该公司将其达芬奇手术系统的安装量增加到9,203台,与2023年第二季度末的8,042套相比增长了14%。
2024年第二季度的收入为20.1亿美元,与2023年第二季度的17.6亿美元相比增长了14%。
归属于Intuitive的2024年第二季度GAAP净收益为5.27亿美元,摊薄每股收益为1.46美元,而2023年第二季度为4.21亿美元,摊薄每股收益为1.18美元。
归属于Intuitive的2024年第二季度非公认会计准则净收益为6.41亿美元,摊薄每股收益为1.78美元,而2023年第二季度为5.07亿美元,摊薄每股收益为1.42美元。
公司简介
$直觉外科公司 (ISRG.US)$,微创护理领域的全球技术领导者,机器人辅助手术的先驱。其产品包括达芬奇手术和离子腔内系统。该公司由弗雷德里克·H·莫尔、约翰·戈登创立 富仁德产业,1995 年 11 月还有 Robert G. Younge,总部位于加利福尼亚州森尼维尔。